الإحصائيات الأساسية
| CIK | 884731 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ARIAD Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| April 7, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ariad Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04033A100 (CUSIP Number) March 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 27, 2017 |
15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36172 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as sp |
|
| February 21, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* ARIAD Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 04033A100 (CUSIP Number) Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steamboat Road, 3rd Floor Greenwich, CT 06830 203-302-2330 |
|
| February 16, 2017 |
S-8 POS As filed with the Securities and Exchange Commission on February 16, 2017 Registration Nos. |
|
| February 16, 2017 |
S-8 POS As filed with the Securities and Exchange Commission on February 16, 2017 Registration Nos. |
|
| February 16, 2017 |
S-8 POS As filed with the Securities and Exchange Commission on February 16, 2017 Registration Nos. |
|
| February 16, 2017 |
S-8 POS As filed with the Securities and Exchange Commission on February 16, 2017 Registration Nos. |
|
| February 16, 2017 |
S-8 POS As filed with the Securities and Exchange Commission on February 16, 2017 Registration Nos. |
|
| February 16, 2017 |
S-8 POS As filed with the Securities and Exchange Commission on February 16, 2017 Registration Nos. |
|
| February 16, 2017 |
S-8 POS As filed with the Securities and Exchange Commission on February 16, 2017 Registration Nos. |
|
| February 16, 2017 |
S-8 POS As filed with the Securities and Exchange Commission on February 16, 2017 Registration Nos. |
|
| February 16, 2017 |
S-8 POS As filed with the Securities and Exchange Commission on February 16, 2017 Registration Nos. |
|
| February 16, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2017 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporati |
|
| February 16, 2017 |
EX-4.1 Exhibit 4.1 EXECUTION VERSION SUPPLEMENTAL INDENTURE, dated as of February 16, 2017, between ARIAD Pharmaceuticals, Inc., a Delaware corporation, as issuer (the ?Company?), and Wells Fargo Bank, National Association, a national banking association, as trustee (the ?Trustee?), to the Indenture, dated as of June 17, 2014 between such parties (the ?Indenture?). All references to the ?Indenture |
|
| February 16, 2017 |
SECOND AMENDED AND RESTATED BY-LAWS OF ARIAD PHARMACEUTICALS, INC. ARTICLE I Stockholders Meetings EX-3.2 Exhibit 3.2 SECOND AMENDED AND RESTATED BY-LAWS OF ARIAD PHARMACEUTICALS, INC. ARTICLE I Stockholders Meetings Section 1.1. Annual Meetings. An annual meeting of stockholders shall be held for the election of directors at such date, time and place as may be fixed by resolution of the Board of Directors from time to time. Section 1.2. Special Meetings. Special meetings of stockholders for an |
|
| February 16, 2017 |
ARIAD Pharmaceuticals, Inc. 125 Binney Street Cambridge, Massachusetts 02142 EX-99.1 Exhibit 99.1 EXECUTION VERSION ARIAD Pharmaceuticals, Inc. 125 Binney Street Cambridge, Massachusetts 02142 February 16, 2017 To: Wells Fargo Bank, National Association 150 E. 42nd St., 40th Floor, New York, NY 10017, Attention: Corporate Trust Services ? Administrator for ARIAD Pharmaceuticals, Inc. To: Holders of 3.625% Convertible Senior Notes due 2019 (the ?Notes?) issued by ARIAD Phar |
|
| February 16, 2017 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ARIAD PHARMACEUTICALS, INC. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ARIAD PHARMACEUTICALS, INC. FIRST: The name of the corporation is ARIAD Pharmaceuticals, Inc. (the Corporation). SECOND: The address of the Corporations registered office in the State of Delaware is The Corporation Trust Center, 1209 Orange Street, Wilmington, Delaware 19801, New Castle County. The name of the Corporations |
|
| February 16, 2017 |
ARIAD Pharmaceuticals SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 5) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ARIAD Pharmaceuticals, Inc. (Name of Subject Company) ARIAD Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, $.001 par value per share (Title of Class of Securities |
|
| February 16, 2017 |
EX-99.(a)(5)(A) Exhibit (a)(5)(A) Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc. – Significantly Enhances Takeda’s Global Oncology Portfolio – – Accretive to FY2018 Underlying Core Earnings – – Reinforces Takeda’s Commitment to Developing Medicines for Patients Living with Cancer – Cambridge, Mass. and Osaka, Japan, February 16, 2017 – Takeda Pharmaceutical Company Limited (TSE: 4502) |
|
| February 16, 2017 |
ARIA / ARIAD Pharmaceuticals, Inc. / TAKEDA PHARMACEUTICAL CO LTD - AMENDMENT NO. 5 TO SC TO-T Amendment No. 5 to SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) ARIAD Pharmaceuticals, Inc. (Name of Subject Company) KIKU MERGER CO., INC. (Offeror) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Parent of Offeror) (Names of |
|
| February 13, 2017 |
EX-10.1 Exhibit 10.1 AMENDED AND RESTATED BUY-IN LICENSE AGREEMENT between ARIAD Pharmaceuticals, Inc. and ARIAD Pharmaceuticals (Europe) Sarl and Incyte Corporation (as guarantor) EXECUTION VERSION TABLE OF CONTENTS ARTICLE 1 – DEFINITIONS 2 ARTICLE 2 – GRANT OF LICENSES 18 ARTICLE 3 – RESERVED TERRITORIES AND NON-COMPETITION 19 ARTICLE 4 – DEVELOPMENT AND COMMERCIALIZATION COMMITTEES 23 ARTICLE |
|
| February 13, 2017 |
10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1 to Form 10-Q) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition periods from to Commission Fi |
|
| February 13, 2017 |
EX-10.2 Exhibit 10.2 EXECUTION VERSION SHARE PURCHASE AGREEMENT by and among INCYTE EUROPE S.À R.L., ARIAD PHARMACEUTICALS (CAYMAN) L.P., ARIAD PHARMACEUTICALS, INC. (AS GUARANTOR), and INCYTE CORPORATION (AS GUARANTOR) MAY 9, 2016 Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registr |
|
| February 10, 2017 |
SC 13G/A 1 ariaa121017.htm WESTFIELD CAPITAL MANAGEMENT COMPANY, L.P. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ariad Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04033A100 (CUSIP Number) December 30, 2016 (Date of Event which Requires Filing of this Stateme |
|
| February 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ARIAD Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04033A100 (CUSIP Number) December 30, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 9, 2017 |
ARIA / ARIAD Pharmaceuticals, Inc. / VANGUARD GROUP INC Passive Investment ariadpharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4 )* Name of issuer: ARIAD Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 04033A100 Date of Event Which Requires Filing of this Statement: December 31, 2016 Check the ap |
|
| February 8, 2017 |
ARIAD Pharmaceuticals AMENDMENT NO. 4 TO SC TO-T Amendment No. 4 to SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) ARIAD Pharmaceuticals, Inc. (Name of Subject Company) KIKU MERGER CO., INC. (Offeror) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Parent of Offeror) (Names of |
|
| February 8, 2017 |
EX-99.(b)(1) Exhibit (b)(1) [TRANSLATION OF THE ORIGINAL VERSION IN JAPANESE] LOAN AGREEMENT February 8, 2017 Borrower Takeda Pharmaceutical Company Limited Lender Sumitomo Mitsui Banking Corporation Takeda Pharmaceutical Company Limited LOAN AGREEMENT dated February 8, 2017 TABLE OF CONTENTS CHAPTER 1. DEFINITIONS 1 1.1 DEFINITIONS 1 CHAPTER 2. TERMS OF LOANS 5 2.1 KEY TERMS OF LOANS 5 2.2 CONDIT |
|
| February 8, 2017 |
EX-99.(b)(2) Exhibit (b)(2) [TRANSLATION OF THE ORIGINAL VERSION IN JAPANESE] LOAN AGREEMENT February 8, 2017 Borrower Takeda Pharmaceutical Company Limited Lender The Bank of Tokyo-Mitsubishi UFJ, Ltd. Takeda Pharmaceutical Company Limited LOAN AGREEMENT dated February 8, 2017 TABLE OF CONTENTS CHAPTER 1. DEFINITIONS 1 1.1 DEFINITIONS 1 CHAPTER 2. TERMS OF LOANS 5 2.1 KEY TERMS OF LOANS 5 2.2 CON |
|
| February 7, 2017 |
ARIAD Pharmaceuticals SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ARIAD Pharmaceuticals, Inc. (Name of Subject Company) ARIAD Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, $.001 par value per share (Title of Class of Securities |
|
| February 6, 2017 |
Exhibit 99.1 ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency CAMBRIDGE, Mass.-(BUSINESS WIRE)-February 6, 2017-ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the submission of a Marketing Authorization Application (MAA) for its investigational oral anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the European M |
|
| February 6, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2017 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commi |
|
| February 1, 2017 |
EX-99.(a)(1)(S) James Kehoe Chief Financial Officer Consolidated Financial Results FY2016 Q3 February 1, 2017 Exhibit (a)(1)(s) Important Notice 3 Cautionary Statement Regarding Forward-Looking Statements This presentation contains forward-looking information related to Takeda, ARIAD and the proposed acquisition of ARIAD by Takeda that involves substantial risks and uncertainties that could cause |
|
| February 1, 2017 |
EX-99.(a)(1)(T) Exhibit (a)(1)(T) Announcer: The discussion during this call will include forward looking statements that are subject to the risks and uncertainties that could cause actual results to differ materially from those projected in the forward looking statements. Additional information regarding these factors is discussed under the cautionary statement regarding forward looking statement |
|
| February 1, 2017 |
ARIAD Pharmaceuticals AMENDMENT NO. 3 TO SC TO-T Amendment No. 3 to SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) ARIAD Pharmaceuticals, Inc. (Name of Subject Company) KIKU MERGER CO., INC. (Offeror) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Parent of Offeror) (Names of |
|
| February 1, 2017 |
EX-99.(a)(1)(R) Exhibit (a)(1)(R) Takeda reports Q3 FY2016 results and improves year-end outlook Underlying YTD results: Revenue +7.4%, Core Earnings +23.5%, Core EPS +31.7% Full year Underlying Core Earnings increased to ?high-teen growth? Strong Q3 year-to-date (YTD) results propelled by Growth Drivers ? Underlying Revenue grew +7.4%, with Takeda?s Growth Drivers (GI, Oncology, CNS and Emerging |
|
| January 30, 2017 |
ARIAD Pharmaceuticals AMENDMENT NO. 2 TO SC TO-T Amendment No. 2 to SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) ARIAD Pharmaceuticals, Inc. (Name of Subject Company) KIKU MERGER CO., INC. (Offeror) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Parent of Offeror) (Names of |
|
| January 30, 2017 |
ARIAD Pharmaceuticals SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ARIAD Pharmaceuticals, Inc. (Name of Subject Company) ARIAD Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, $.001 par value per share (Title of Class of Securities |
|
| January 24, 2017 |
ARIAD Pharmaceuticals SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ARIAD Pharmaceuticals, Inc. (Name of Subject Company) ARIAD Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, $.001 par value per share (Title of Class of Securities |
|
| January 24, 2017 |
ARIAD Pharmaceuticals SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) ARIAD Pharmaceuticals, Inc. (Name of Subject Company) KIKU MERGER CO., INC. (Offeror) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Parent of Offeror) (Names of Filing Persons) Common sto |
|
| January 24, 2017 |
ARIAD Pharmaceuticals SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ARIAD Pharmaceuticals, Inc. (Name of Subject Company) ARIAD Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, $.001 par value per share (Title of Class of Securities |
|
| January 24, 2017 |
ARIAD Pharmaceuticals, Inc. Employee FAQs January 23, 2017 EX-99.(a)(13) Exhibit (a)(13) ARIAD Pharmaceuticals, Inc. Employee FAQs January 23, 2017 1. What was announced? Why is ARIAD entering into this transaction with Takeda? ? On January 9, 2017, we announced that ARIAD has entered into a definitive agreement to be acquired by Takeda. ? The transaction with Takeda will allow us to accelerate ARIAD?s mission to discover, develop and deliver precision th |
|
| January 19, 2017 |
SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 19, 2017 |
EX-99.(a)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of ARIAD Pharmaceuticals, Inc. at $24.00 Net Per Share by Kiku Merger Co., Inc. an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M. EASTERN TIME ON WEDNESDAY, FEBRUARY 15, 2017, UNLESS THE OFFER IS E |
|
| January 19, 2017 |
EX-99.(a)(1)(F) Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely pursuant to the Offer to Purchase, dated January 19, 2017, and the related Letter of Transmittal and any amendments or |
|
| January 19, 2017 |
EX-99.(a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of ARIAD Pharmaceuticals, Inc. a Delaware corporation at $24.00 NET PER SHARE Pursuant to the Offer to Purchase Dated January 19, 2017 by Kiku Merger Co., Inc. an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M. EASTERN TIME ON |
|
| January 19, 2017 |
EX-99.(a)(1)(C) Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY To Tender Shares of Common Stock of ARIAD Pharmaceuticals, Inc. a Delaware corporation at $24.00 NET PER SHARE Pursuant to the Offer to Purchase Dated January 19, 2017 by Kiku Merger Co., Inc. an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M. EASTERN |
|
| January 19, 2017 |
[Remainder of Page Intentionally Left Blank] EX-99.(d)(2) Exhibit (d) (2) EXECUTION COPY December 18, 2016 Takeda Pharmaceutical Company Limited 1-1, Doshomachi 4-chome Chuo-ku, Osaka-shi Osaka 540-8645, Japan Ladies and Gentlemen: In connection with your consideration of a possible consensual transaction (the Transaction) with ARIAD Pharmaceuticals, Inc. and/or its affiliates (collectively, with such affiliates, the Company), the Compan |
|
| January 19, 2017 |
Takeda Commences Cash Tender Offer for all Outstanding Shares of ARIAD Pharmaceuticals, Inc. EX-99.(a)(1)(Q) Exhibit (a)(1)(Q) Takeda Commences Cash Tender Offer for all Outstanding Shares of ARIAD Pharmaceuticals, Inc. Osaka, Japan, January 20, 2017 and Cambridge, Massachusetts, USA, January 19, 2017 ? Takeda Pharmaceutical Company Limited (TSE: 4502) (?Takeda?) today announced the commencement of the cash tender offer by its wholly-owned indirect subsidiary, Kiku Merger Co., Inc., for a |
|
| January 19, 2017 |
EX-99.(a)(1)(E) Exhibit (a)(1)(E) Offer to Purchase for Cash All Outstanding Shares of Common Stock of ARIAD Pharmaceuticals, Inc. a Delaware corporation at $24.00 Net Per Share Pursuant to the Offer to Purchase Dated January 19, 2017 by Kiku Merger Co., Inc. an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M. EASTE |
|
| January 19, 2017 |
EX-99.(d)(3) Exhibit (d) (3) Better Health, Brighter Future December 26, 2016 Board of Directors Ariad Pharmaceuticals, Inc. 26 Landsdowne Street Cambridge, MA 02139 Ladies and Gentlemen: This letter agreement (this Letter Agreement) sets forth certain understandings between Takeda Pharmaceutical Company Limited (Buyer), and Ariad Pharmaceuticals, Inc. (the Company) with respect to discussio |
|
| January 19, 2017 |
SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ARIAD PHARMACEUTICALS, INC. (Name of Subject Company) KIKU MERGER CO., INC. (Offeror) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.001 per |
|
| January 19, 2017 |
EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase for Cash All Outstanding Shares of Common Stock of ARIAD Pharmaceuticals, Inc. a Delaware corporation at $24.00 Net Per Share Pursuant to the Offer to Purchase Dated January 19, 2017 by Kiku Merger Co., Inc. an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M. EASTE |
|
| January 18, 2017 |
ARIA / ARIAD Pharmaceuticals, Inc. / TAKEDA PHARMACEUTICAL CO LTD - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240. |
|
| January 18, 2017 |
[Remainder of Page Intentionally Left Blank] EX-99.3 EXHIBIT 3 EXECUTION COPY December 18, 2016 Takeda Pharmaceutical Company Limited 1-1, Doshomachi 4-chome Chuo-ku, Osaka-shi Osaka 540-8645, Japan Ladies and Gentlemen: In connection with your consideration of a possible consensual transaction (the “Transaction”) with ARIAD Pharmaceuticals, Inc. and/or its affiliates (collectively, with such affiliates, the “Company”), the Company is prepar |
|
| January 18, 2017 |
99.EX-4 EXHIBIT 4 AGREEMENT OF JOINT FILING This joint filing agreement (this “Agreement”) is made and entered into as of this 18th day of January, 2017, by and among Takeda Pharmaceutical Company Limited, Kiku Merger Co., Inc., TPA Holding I, Inc. and TPA Holding II, Inc. The parties to this Agreement hereby agree to prepare jointly and file timely (and otherwise to deliver as appropriate) all fi |
|
| January 11, 2017 |
EX-99.1 Exhibit 99.1 * * * * * Christophe Weber: Thank you. Good afternoon everyone. It?s a great pleasure to be with you again this year. What I?m planning to do is to give you an update about Takeda and the transformation of Takeda. We started this transformation two years ago. Of course, we had a big event today with the acquisition of ARIAD. I will share with you that perspective as well about |
|
| January 11, 2017 |
EX-99.2 Exhibit 99.2 The discussion during this call will include forward-looking statements that are subject to the risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. Additional information regarding these factors is discussed under the ?Cautionary Statement Regarding Forward-Looking Statements? section in the press |
|
| January 11, 2017 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ARIAD PHARMACEUTICALS, INC. (Name of Subject Company) KIKU MERGER CO., INC. (Offeror) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.001 per |
|
| January 10, 2017 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ARIAD PHARMACEUTICALS, INC. (Name of Subject Company) KIKU MERGER CO., INC. (Offeror) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.001 per |
|
| January 10, 2017 |
EX-99.2 Conference Call Takeda to Acquire ARIAD Pharmaceuticals Significantly Enhances Takeda's Global Oncology Portfolio January 10, 2017 Christophe Weber President & Chief Executive Officer Exhibit 99.2 Important Notice Forward-Looking Statements This presentation contains forward-looking statements regarding Takeda?s future business, financial position and results of operations, including estim |
|
| January 10, 2017 |
EX-99.1 Strategic Transformation Driving Profitable Growth J.P. Morgan Healthcare Conference 2017 January 9, 2017 Christophe Weber President & Chief Executive Of?cer Exhibit 99.1 Important Notice Forward-Looking Statements This presentation contains forward-looking statements regarding Takeda?s future business, financial position and results of operations, including estimates, forecasts, targets a |
|
| January 10, 2017 |
Exhibit 99.2 News Release FOR IMMEDIATE RELEASE ARIAD Enters into Definitive Agreement to be Acquired by Takeda for $5.2 billion ARIAD Stockholders to Receive $24.00 per Share in Cash Cambridge, Mass. January 9, 2017 ? ARIAD Pharmaceuticals (NASDAQ:ARIA) (?ARIAD?) today announced it has entered into a definitive agreement to be acquired by Takeda Pharmaceutical Company Limited (TSE: 4502) (?Takeda |
|
| January 10, 2017 |
CALL OPTION AND WARRANT TERMINATION AGREEMENT Exhibit 10.1 CALL OPTION AND WARRANT TERMINATION AGREEMENT This CALL OPTION AND WARRANT TERMINATION AGREEMENT (this ?Termination Agreement?) is made as of January 8, 2017 between JPMorgan Chase Bank, National Association, London Branch (?Dealer?) and ARIAD Pharmaceuticals, Inc. (?Counterparty?), a Delaware corporation. WHEREAS, Dealer and Counterparty are parties to the base call option transactio |
|
| January 10, 2017 |
ARIAD Pharmaceuticals, Inc. 125 Binney Street Cambridge, Massachusetts 02142 Exhibit 99.4 ARIAD Pharmaceuticals, Inc. 125 Binney Street Cambridge, Massachusetts 02142 January 9, 2017 To: Wells Fargo Bank, National Association 150 E. 42nd St., 40th Floor, New York, NY 10017, Attention: Corporate Trust Services ? Administrator for ARIAD Pharmaceuticals, Inc. To: Holders of 3.625% Convertible Senior Notes due 2019 (the ?Notes?) issued by ARIAD Pharmaceuticals, Inc.; CUSIP: 04 |
|
| January 10, 2017 |
Exhibit 99.1 Takeda to Acquire ARIAD Pharmaceuticals, Inc. ? Significantly Enhances Takeda?s Global Oncology Portfolio ? ? Accretive to FY2018 Underlying Core Earnings ? ? Reinforces Takeda?s Commitment to Developing Medicines for Patients Living with Cancer ? Strategic Highlights ? Highly strategic deal which transforms global oncology portfolio and pipeline by expanding into solid tumors and rei |
|
| January 10, 2017 |
Exhibit 99.3 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this ?Agreement?), dated as of January 8, 2017, is entered into by and among Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan (?Parent?), Kiku Merger Co., Inc., a Delaware corporation and an indirect wholly-owned subsidiary of Parent (?Merger Sub?), and the individual or entity set fo |
|
| January 10, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2017 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commis |
|
| January 10, 2017 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER between ARIAD PHARMACEUTICALS, INC., TAKEDA PHARMACEUTICAL COMPANY LIMITED, and KIKU MERGER CO., INC. JANUARY 8, 2017 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 2 Section 1.01 Definitions 2 Section 1.02 Other Definitional and Interpretative Provisions 14 ARTICLE 2 THE OFFER AND THE MERGER 14 Section 2.01 The Offer 14 Section 2.02 Company |
|
| January 10, 2017 |
ARIA / ARIAD Pharmaceuticals, Inc. / Sarissa Capital Management LP - SC 13D/A Activist Investment SC 13D/A 1 d285727dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8 )* ARIAD Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 04033A100 (CUSIP Number) Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steamboat Road Gree |
|
| January 9, 2017 |
EX-99.4 Exhibit 99.4 Takeda Oncology We are excited to announce we?ve entered into a definitive agreement to acquire Ariad Pharmaceuticals. Read important information here: http://takeda.news/2j9ordj |
|
| January 9, 2017 |
EX-99.5 Exhibit 99.5 Takeda Oncology We are excited to announce we?ve entered into a definitive agreement to acquire Ariad Pharmaceuticals. Read the full announcement: http://bit.ly/2iUrqX7 and important information below: Additional Information The tender offer described in this document has not yet commenced. This document is provided for informational purposes only and does not constitute an of |
|
| January 9, 2017 |
A Message from Takeda President and CEO Christophe Weber re: Takeda Acquisition of Ariad EX-99.6 Exhibit 99.6 A Message from Takeda President and CEO Christophe Weber re: Takeda Acquisition of Ariad January 9, 2017 Dear all, Following the announcement that Takeda has reached agreement to acquire Ariad Pharmaceuticals, I?d like to extend a warm greeting on behalf of everyone at Takeda. Ariad has an exciting portfolio of targeted therapies that are highly complementary to Takeda?s oncol |
|
| January 9, 2017 |
EX-99.3 Exhibit 99.3 @TakedaOncology #BREAKING: Excited to announce our acquisition of @AriadPharm. Read important information here: http://takeda.news/2j9ordj |
|
| January 9, 2017 |
EX-99.1 Exhibit 99.1 News Release FOR IMMEDIATE RELEASE ARIAD Enters into Definitive Agreement to be Acquired by Takeda for $5.2 billion ARIAD Stockholders to Receive $24.00 per Share in Cash Cambridge, Mass. January 9, 2017 ? ARIAD Pharmaceuticals (NASDAQ:ARIA) (?ARIAD?) today announced it has entered into a definitive agreement to be acquired by Takeda Pharmaceutical Company Limited (TSE: 4502) |
|
| January 9, 2017 |
EX-99.2 Exhibit 99.2 Takeda to Acquire ARIAD Pharmaceuticals, Inc. ? Significantly Enhances Takeda?s Global Oncology Portfolio ? ? Accretive to FY2018 Underlying Core Earnings ? ? Reinforces Takeda?s Commitment to Developing Medicines for Patients Living with Cancer ? Strategic Highlights ? Highly strategic deal which transforms global oncology portfolio and pipeline by expanding into solid tumors |
|
| January 9, 2017 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ARIAD PHARMACEUTICALS, INC. (Name of Subject Company) KIKU MERGER CO., INC. (Offeror) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.001 per |
|
| January 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ARIAD Pharmaceuticals, Inc. (Name of Subject Company) ARIAD Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 04033A100 |
|
| January 9, 2017 |
Subject Line: CEO Message Regarding ARIAD/Takeda Transaction Announcement Exhibit 99.3 Subject Line: CEO Message Regarding ARIAD/Takeda Transaction Announcement January 9, 2017 Dear colleagues, I have important news that I want to share with you directly ? we have just announced that ARIAD has entered into a definitive agreement to be acquired by Takeda Pharmaceuticals. This transaction not only allows us to accelerate ARIAD?s mission to discover, develop and deliver pr |
|
| January 9, 2017 |
Exhibit 99.2 News Release FOR IMMEDIATE RELEASE ARIAD Enters into Definitive Agreement to be Acquired by Takeda for $5.2 billion ARIAD Stockholders to Receive $24.00 per Share in Cash Cambridge, Mass. January 9, 2017 ? ARIAD Pharmaceuticals (NASDAQ:ARIA) (?ARIAD?) today announced it has entered into a definitive agreement to be acquired by Takeda Pharmaceutical Company Limited (TSE: 4502) (?Takeda |
|
| January 9, 2017 |
ARIAD Pharmaceuticals, Inc. 125 Binney Street Cambridge, Massachusetts 02142 Exhibit 99.4 ARIAD Pharmaceuticals, Inc. 125 Binney Street Cambridge, Massachusetts 02142 January 9, 2017 To: Wells Fargo Bank, National Association 150 E. 42nd St., 40th Floor, New York, NY 10017, Attention: Corporate Trust Services ? Administrator for ARIAD Pharmaceuticals, Inc. To: Holders of 3.625% Convertible Senior Notes due 2019 (the ?Notes?) issued by ARIAD Pharmaceuticals, Inc.; CUSIP: 04 |
|
| January 9, 2017 |
Exhibit 99.1 Takeda to Acquire ARIAD Pharmaceuticals, Inc. Significantly Enhances Takedas Global Oncology Portfolio Accretive to FY2018 Underlying Core Earnings Reinforces Takedas Commitment to Developing Medicines for Patients Living with Cancer Strategic Highlights · Highly strategic deal which transforms global oncology portfolio and pipeline by expanding into solid tumors and rei |
|
| December 8, 2016 |
Exhibit 99.2 ARIAD Announces Data Presentations at American Society of Hematology Meeting ~Final report from Phase 1 study of ponatinib includes approximately five-year median follow-up; Major Molecular Response (MMR) rate was 56 percent ~Pooled Phase 1 and PACE analysis of CP-CML patients with T315I shows 83 percent estimated to maintain major cytogenetic response at four years CAMBRIDGE, Mass. & |
|
| December 8, 2016 |
Exhibit 99.3 ARIAD?s Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival in ALTA Study - Analysis Also Demonstrated Intracranial Median Progression-Free Survival (PFS) of 18.4 Months - 55 Percent Confirmed Systemic Objective Response Rate - Investor and Analyst Webcast to be Held Today at 4:00 p.m. Central European Time (10:00 a.m. Eastern Time) CA |
|
| December 8, 2016 |
ARIAD Pharmaceuticals ARIAD PHARMACEUTICALS, INC. 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commi |
|
| December 8, 2016 |
Exhibit 99.1 ARIAD Presents Updated Brigatinib Data with 18.4 Months Median Intracranial Progression Free Survival (PFS) in ALK+ NSCLC Patients with CNS Metastases at the World Conference on Lung Cancer ~ Investor and analyst call to be held on Wednesday, December 7 at 4:00 p.m. Central European Time (10:00 a.m. Eastern Time) CAMBRIDGE, Mass. & VIENNA-(BUSINESS WIRE)-December 5, 2016-ARIAD Pharmac |
|
| December 7, 2016 |
Executive Employment Agreement EX-10.1 Exhibit 10.1 Executive Employment Agreement ARIAD Pharmaceuticals, Inc. (the Company) a Delaware corporation, and Timothy P. Clackson, Ph.D. (the Employee) enter into the following Executive Employment Agreement as of the 1st day of December, 2016 (hereafter, the Agreement). WHEREAS, the Company and the Employee previously entered into an executive agreement on May 15, 2010, as amend |
|
| December 7, 2016 |
8-K 1 d238507d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 1, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or Other Jurisdiction |
|
| December 7, 2016 |
Executive Employment Agreement EX-10.2 Exhibit 10.2 Executive Employment Agreement ARIAD Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, and Daniel M. Bollag, Ph.D. (the ?Employee?) enter into the following Executive Employment Agreement as of the 1st day of December, 2016 (hereafter, the ?Agreement?). WHEREAS, the Company and the Employee previously entered into an executive agreement on May 15, 2010, as amended |
|
| December 7, 2016 |
Executive Employment Agreement EX-10.3 Exhibit 10.3 Executive Employment Agreement ARIAD Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, and Hugh M. Cole (the ?Employee?) enter into the following Executive Employment Agreement as of the 1st day of December, 2016 (hereafter, the ?Agreement?). WHEREAS, the Company and the Employee previously entered into an executive agreement on February 28, 2014, which the Compan |
|
| December 7, 2016 |
Mail Stop 4546 December 7, 2016 VIA EDGAR AND HAND DELIVERY Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7010 Re: ARIAD Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2015 Filed February 29, 2016 Form 10-Q for the Quarterly Period Ended September 30, 2 |
|
| November 30, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Comm |
|
| November 30, 2016 |
Exhibit 99.1 ARIAD Announces FDA Full Approval and Label Update for Iclusig? (ponatinib) Based on Long-Term Efficacy and Safety Data from Phase 2 PACE Clinical Trial Full approval granted through completion of accelerated approval commitments for rare cancer patients who may have no other targeted treatment options New label update for CP-CML reflects 55 percent major cytogenetic response rate (MC |
|
| November 18, 2016 |
ARIAD Pharmaceuticals ARIAD PHARMACEUTICALS, INC. 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Comm |
|
| November 18, 2016 |
Exhibit 99.1 ARIAD Announces Data Presentations at the World Conference on Lung Cancer ~ Investigational Medicine Brigatinib Demonstrates 53 Percent Confirmed Objective Response Rate and 15.6-Month Median Progression-Free Survival by Independent Review Committee Assessment in ALTA Study Abstract ~ WCLC Oral and Poster Presentations to Include Approximately Three Months of Additional Follow-up Comp |
|
| November 8, 2016 |
Quarterly Report - 10-Q Q3 2016 FILING Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 8, 2016 |
Executive Employment Agreement Exhibit 10.1 Executive Employment Agreement ARIAD Pharmaceuticals, Inc. (the “Company”) a Delaware corporation, and Elona Kogan (the “Employee”) enter into the following Executive Employment Agreement as of the 15th day of July, 2016 (hereafter, the “Agreement”). WHEREAS, the Company wishes to offer the Employee employment according to the following terms and conditions; WHEREAS, the Employee wish |
|
| November 7, 2016 |
Exhibit 99.1 ARIAD Reports Third Quarter 2016 Financial Results ~Brigatinib granted Priority Review with a PDUFA date of April 29, 2017 ~ Regulatory approval of Iclusig? in Japan ~ Enrollment continues in OPTIC, OPTIC-2L, ALTA-1L, AP32788 trials highlighting ARIAD's continued R&D investment for patients with rare cancers ~ U.S. product revenue of $33.6 million for the quarter (~66% growth from pri |
|
| November 7, 2016 |
ARIAD Pharmaceuticals ARIAD PHARMACEUTICALS, INC. 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commi |
|
| October 31, 2016 |
8-K 1 a51450187.htm ARIAD PHARMACEUTICALS, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 ( |
|
| October 31, 2016 |
Exhibit 99.1 ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Filing for Brigatinib Brigatinib Granted Priority Review, with a PDUFA Date of April 29, 2017 CAMBRIDGE, Mass.-(BUSINESS WIRE)-October 31, 2016-ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ARIAD?s |
|
| September 29, 2016 |
Exhibit 99.1 ARIAD Announces Regulatory Approval for Iclusig? (ponatinib) in Japan Approval triggers $10 million milestone payment to ARIAD CAMBRIDGE, Mass.-(BUSINESS WIRE)-September 28, 2016-ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) has received approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) f |
|
| September 29, 2016 |
ARIAD Pharmaceuticals ARIAD PHARMACEUTICALS, INC. 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Com |
|
| August 30, 2016 |
Exhibit 99.1 ARIAD Completes Rolling Submission of New Drug Application for Brigatinib to the U.S. Food and Drug Administration CAMBRIDGE, Mass.-(BUSINESS WIRE)-August 30, 2016-ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced it has completed the rolling submission of the New Drug Application (NDA) for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the U.S. |
|
| August 30, 2016 |
8-K 1 a51410050.htm ARIAD PHARMACEUTICALS, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (S |
|
| August 8, 2016 |
ARIAD Pharmaceuticals Q2 2016 10-Q - AS OF 6/30/16 (Quarterly Report) Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 8, 2016 |
Exhibit 10.1 EXECUTION VERSION AMENDED AND RESTATED BUY-IN LICENSE AGREEMENT between ARIAD Pharmaceuticals, Inc. and ARIAD Pharmaceuticals (Europe) Sarl and Incyte Corporation (as guarantor) TABLE OF CONTENTS ARTICLE 1 – DEFINITIONS 2 ARTICLE 2 – GRANT OF LICENSES 18 ARTICLE 3 – RESERVED TERRITORIES AND NON-COMPETITION 19 ARTICLE 4 – DEVELOPMENT AND COMMERCIALIZATION COMMITTEES 23 ARTICLE 5 – DEVE |
|
| August 8, 2016 |
Exhibit 10.3 EXECUTION VERSION AMENDMENT NO. 1 TO RIAA This AMENDMENT NO. 1 TO RIAA (this “Amendment”) is made and entered into as of May 9, 2016 by and between ARIAD Pharmaceuticals, Inc., a Delaware corporation (“ARIAD” or the “Company”), and PDL BioPharma, Inc., a Delaware corporation (“Purchaser”), each party to that certain Revenue Interest Assignment Agreement, dated as of July 28, 2015 (as |
|
| August 8, 2016 |
ARIAD PHARMACEUTICALS, INC. 2014 LONG-TERM INCENTIVE PLAN FORM OF RESTRICTED STOCK UNIT AGREEMENT Exhibit 10.8 ARIAD PHARMACEUTICALS, INC. 2014 LONG-TERM INCENTIVE PLAN FORM OF RESTRICTED STOCK UNIT AGREEMENT This Restricted Stock Unit Agreement certifies that, pursuant to the ARIAD Pharmaceuticals, Inc. 2014 Long Term Incentive Plan (the “2014 Plan”), the Board of Directors of ARIAD Pharmaceuticals, Inc. (the “Company”) has granted the right to receive shares of common stock, $.001 par value |
|
| August 8, 2016 |
PARTIAL RELEASE OF SECURITY INTEREST Exhibit 10.4 EXECUTION VERSION PARTIAL RELEASE OF SECURITY INTEREST THIS PARTIAL RELEASE OF SECURITY INTEREST (this “Release”), dated as of May 9, 2016 is made by PDL BIOPHARMA, INC., a Delaware corporation (the “Purchaser”) party to that certain Revenue Interest Assignment Agreement, dated as of July 28, 2015 by and between ARIAD PHARMACEUTICALS, INC., a Delaware corporation, (the “Company”) (as |
|
| August 8, 2016 |
ARIAD PHARMACEUTICALS, INC. 2014 LONG-TERM INCENTIVE PLAN FORM OF PERFORMANCE SHARE AGREEMENT Exhibit 10.9 ARIAD PHARMACEUTICALS, INC. 2014 LONG-TERM INCENTIVE PLAN FORM OF PERFORMANCE SHARE AGREEMENT This Performance Share Agreement certifies that, pursuant to the ARIAD Pharmaceuticals, Inc. 2014 Long Term Incentive Plan (the “2014 Plan”), the Compensation Committee of the Board of Directors of ARIAD Pharmaceuticals, Inc. (the “Company”) has granted the Participant the right to receive sh |
|
| August 8, 2016 |
Exhibit 10.2 EXECUTION VERSION SHARE PURCHASE AGREEMENT by and among INCYTE EUROPE S.à r.l., ARIAD PHARMACEUTICALS (CAYMAN) L.P., ARIAD PHARMACEUTICALS, INC. (AS GUARANTOR), and INCYTE CORPORATION (AS GUARANTOR) May 9, 2016 Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s ap |
|
| August 8, 2016 |
Executive Employment Agreement Exhibit 10.6 Executive Employment Agreement ARIAD Pharmaceuticals, Inc. (the “Company”) a Delaware corporation, and Jayne M. Gansler (the “Employee”) enter into the following Executive Employment Agreement as of the 1st day of June, 2016 (hereafter, the “Agreement”). WHEREAS, the Company wishes to offer the Employee employment according to the following terms and conditions; WHEREAS, the Employee |
|
| August 8, 2016 |
Executive Employment Agreement Exhibit 10.5 Executive Employment Agreement ARIAD Pharmaceuticals, Inc. (the “Company”) a Delaware corporation, and Jennifer Herron (the “Employee”) enter into the following Executive Employment Agreement as of the 23rd day of May, 2016 (hereafter, the “Agreement”). WHEREAS, the Company wishes to offer the Employee employment according to the following terms and conditions; WHEREAS, the Employee w |
|
| August 8, 2016 |
ARIAD PHARMACEUTICALS, INC. 2014 LONG-TERM INCENTIVE PLAN FORM OF OPTION AGREEMENT Exhibit 10.7 ARIAD PHARMACEUTICALS, INC. 2014 LONG-TERM INCENTIVE PLAN FORM OF OPTION AGREEMENT This Option Agreement certifies that, pursuant to the ARIAD Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the “2014 Plan”), the Board of Directors of ARIAD Pharmaceuticals, Inc. (the “Company”) has granted an option (the “Option”) to purchase shares of the Company’s common stock, $.001 par value |
|
| July 28, 2016 |
ARIAD Pharmaceuticals ARIAD PHARMACEUTICALS, INC. 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commissi |
|
| July 28, 2016 |
Exhibit 99.1 ARIAD Reports Second Quarter and First Half 2016 Financial Results ~Product revenue of $65.3 million for Q2 2016, including one-time $25.5 million from France ~U.S. product revenue of $32.6 million for Q2 2016, representing 50% growth from prior year ~Conference call scheduled today at 8:30 a.m. ET CAMBRIDGE, Mass.-(BUSINESS WIRE)-July 28, 2016-ARIAD Pharmaceuticals, Inc. (NASDAQ: ARI |
|
| July 22, 2016 |
ARIAD Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) |
|
| July 22, 2016 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF ARIAD PHARMACEUTICALS, INC. (Pursuant to Sections 141 and 242 of the General Corporation Law of the State of Delaware) ARIAD Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the Delaware General Corporatio |
|
| July 19, 2016 |
elonakogan15jul16 |
|
| June 8, 2016 |
ARIAD Pharmaceuticals NOTICE AND ACCESS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| June 8, 2016 |
ARIAD Pharmaceuticals DEFINITIVE PROXY STATEMENT Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 8, 2016 |
jaynegansler |
|
| June 7, 2016 |
EX-99.2 Exhibit 99.2 News Release ARIAD PRESENTS DATA FROM MUTATIONAL PROFILING IN CRIZOTINIB-RESISTANT PATIENTS TREATED WITH INVESTIGATIONAL MEDICINE BRIGATINIB SHOWING SIMILAR RESPONSE RATES IN PATIENTS WITH AND WITHOUT SECONDARY ALK MUTATIONS ~ Brigatinib Achieves Confirmed Response in Patient with G1202R Mutation that Emerges Following Treatment with Current Approved Therapies Chicago, IL and |
|
| June 7, 2016 |
EX-99.1 Exhibit 99.1 News Release ARIAD PRESENTS LONG-TERM PHASE 1/2 TRIAL FOLLOW UP ON INVESTIGATIONAL DRUG BRIGATINIB WITH MEDIAN TIME ON TREATMENT OF 17 MONTHS IN ALK+ NSCLC PATIENTS ~ Longest Time on Treatment Now More Than 3.5 Years for Patients with ALK+ Non-Small Cell Lung Cancer ~ Data from Phase 1/2 Clinical Trial Presented at 2016 ASCO Meeting Chicago, IL and Cambridge, MA ? June 4, 2016 |
|
| June 7, 2016 |
ARIAD Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commi |
|
| June 7, 2016 |
EX-99.3 Exhibit 99.3 News Release FOR IMMEDIATE RELEASE ARIAD?S INVESTIGATIONAL MEDICINE BRIGATINIB DEMONSTRATES 54 PERCENT CONFIRMED OBJECTIVE RESPONSE RATE AND 12.9-MONTH MEDIAN PROGRESSION-FREE SURVIVAL IN ALTA STUDY ~ 67 Percent Confirmed Intracranial Objective Response Rate in Patients with Measurable Brain Metastases ~ Data from Pivotal Study in Refractory ALK Positive Non-Small Cell Lung Ca |
|
| June 2, 2016 |
EX-99.1 Exhibit 99.1 News Release ARIAD COMPLETES THE SALE OF ITS EUROPEAN OPERATIONS AND OUT-LICENSE OF EUROPEAN RIGHTS TO ICLUSIG? ~Divestiture to Incyte Strengthens Financial Position ~ARIAD Receives $140 Million Upfront Payment, $135 million to be Received in Potential Oncology Milestones, Tiered Royalty Payments of Between 32% and 50% Cambridge, MA, June 2, 2016 ? ARIAD Pharmaceuticals, Inc. |
|
| June 2, 2016 |
ARIAD Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation or orga |
|
| May 27, 2016 |
ARIAD Pharmaceuticals PRELIMINARY PROXY STATEMENT Preliminary Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 26, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commi |
|
| May 26, 2016 |
ARIAD ANNOUNCES APPOINTMENT OF JENNIFER L. HERRON AS CHIEF COMMERCIAL OFFICER EX-99.1 Exhibit 99.1 News Release ARIAD ANNOUNCES APPOINTMENT OF JENNIFER L. HERRON AS CHIEF COMMERCIAL OFFICER Cambridge, MA, May 24, 2016?- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Jennifer L. Herron as executive vice president, chief commercial officer, effective May 31, 2016. She will report to ARIAD?s president and chief executive officer, Paris Panayiotop |
|
| May 20, 2016 |
ARIAD Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) ( |
|
| May 19, 2016 |
ARIAD Pharmaceuticals ARIAD PHARMACEUTICALS, INC. 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: (Date of earliest event reported) May 18, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commissio |
|
| May 19, 2016 |
Exhibit 99.1 ARIAD Announces Data Presentations at the 2016 ASCO Annual Meeting ~Oral Presentation of Clinical Data from ALTA Pivotal Trial on Monday, June 6, 2016 ~ ASCO Presentation to Include Approximately 3 Months of Additional Follow-up Compared to Abstract ~Investor and Analyst Briefing to be Held at ASCO on Monday, June 6 at 7 a.m. CT CAMBRIDGE, Mass.-(BUSINESS WIRE)-May 18, 2016-ARIAD Phar |
|
| May 10, 2016 |
Exhibit 99.1 ARIAD Reports First Quarter 2016 Financial Results and Progress on Strategic Review ~Recorded Net Product Revenue of $33.6 million for the first quarter of 2016; growth of 41% from prior year ~Provides guidance for 2016, including strengthened year-end cash position, following announced Incyte transaction: Global product and royalty revenue of $170 million to $180 million R&D expense |
|
| May 10, 2016 |
ARIAD Pharmaceuticals ARIAD PHARMACEUTICALS, INC. 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commissio |
|
| May 10, 2016 |
ARIAD Pharmaceuticals 10-Q Q1 2016 (Quarterly Report) 10-Q 1 a2016q110-q.htm 10-Q Q1 2016 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition peri |
|
| May 9, 2016 |
ARIAD Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation or organ |
|
| May 9, 2016 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE INCYTE AND ARIAD ANNOUNCE AGREEMENT FOR INCYTE TO ACQUIRE ARIAD?S EUROPEAN OPERATIONS AND IN-LICENSE ICLUSIG? IN EUROPE ~Incyte to Accelerate the Expansion of its European Organization to Optimize the Potential of Future Product Launches in Europe ~ARIAD to Receive $140 Million Upfront Payment, Plus Tiered Royalties on European Sales of Iclusig and Potent |
|
| May 6, 2016 |
ARIAD Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (C |
|
| May 6, 2016 |
bickerstaff |
|
| May 6, 2016 |
haimovitz |
|
| April 29, 2016 |
EX-4.1 Exhibit 4.1 THIS CERTIFIES THAT is the owner of CUSIP DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER AGENT AND REGISTRAR, FULLY PAID AND NON-ASSESSABLE SHARES OF THE COMMON STOCK, $.001 PAR VALUE, OF ARIAD Pharmaceuticals, Inc. transferable only on the books of the Corporation by the holder hereof in person or by duly authorized attorney upon surrender of thi |
|
| April 29, 2016 |
ARIAD Pharmaceuticals FORM 10-K/A (Annual Report) Form 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 29, 2016 |
Executive Employment Agreement EX-10.15 Exhibit 10.15 Executive Employment Agreement ARIAD Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, and Manmeet Singh Soni (the ?Employee?) enter into the following Executive Employment Agreement as of the 9th day of March, 2016 (hereafter, the ?Agreement?). WHEREAS, the Company wishes to offer the Employee employment according to the following terms and conditions; WHEREAS, |
|
| April 25, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) |
|
| March 29, 2016 |
ARIAD Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) |
|
| March 29, 2016 |
EX-99.1 Exhibit 99.1 News Release FOR IMMEDIATE RELEASE ARIAD ANNOUNCES REDUCTION IN WORKFORCE AS PART OF ONGOING COMPANY-WIDE STRATEGIC REVIEW Approximately 25 percent of its Headquarter Positions to be Impacted Cambridge, MA, March 29, 2016 ? ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it is reducing approximately 25 percent of its headquarter positions. The reduction include |
|
| March 21, 2016 |
sonipowerofattord67 |
|
| March 18, 2016 |
EX-99.2 Exhibit 99.2 FORM OF STOCK OPTION AGREEMENT GOVERNED BY THE TERMS, CONDITIONS AND LIMITATIONS OF THE ARIAD PHARMACEUTICALS, INC. 2014 LONG-TERM INCENTIVE PLAN This Stock Option Agreement (this ?Option Agreement?) certifies that the Board of Directors of ARIAD Pharmaceuticals, Inc. (the ?Company?) has granted an option (the ?Option?) to purchase shares of the Company?s common stock, $.001 p |
|
| March 18, 2016 |
EX-99.3 Exhibit 99.3 FORM OF 2016 PERFORMANCE SHARE AGREEMENT GOVERNED BY THE TERMS, CONDITIONS AND LIMITATIONS OF THE ARIAD PHARMACEUTICALS, INC. 2014 LONG-TERM INCENTIVE PLAN This Performance Share Agreement (this Performance Share Agreement) certifies that the Board of Directors of ARIAD Pharmaceuticals, Inc. (the Company) has granted the Participant the right to receive shares of common st |
|
| March 18, 2016 |
EX-99.1 Exhibit 99.1 STOCK OPTION AGREEMENT GOVERNED BY THE TERMS, CONDITIONS AND LIMITATIONS OF THE ARIAD PHARMACEUTICALS, INC. 2014 LONG-TERM INCENTIVE PLAN This Stock Option Agreement (this ?Option Agreement?) certifies that the Board of Directors of ARIAD Pharmaceuticals, Inc. (the ?Company?) has granted an option (the ?Option?) to purchase shares of the Company?s common stock, $.001 par value |
|
| March 18, 2016 |
ARIAD Pharmaceuticals FORM S-8 FORM S-8 As filed with the Securities and Exchange Commission on March 18, 2016 REGISTRATION NO. |
|
| March 18, 2016 |
Exhibit 10.1 AMENDMENT TO AGREEMENT This AMENDMENT (the ? Amendment?) is made as of March 17, 2016, by and among ARIAD Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the ? Company?), and the entities listed on Schedule A hereto (collectively, the ? Sarissa Group?). WHEREAS, the Company and the Sarissa Group are parties to that certain Agreement |
|
| March 18, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commiss |
|
| March 18, 2016 |
SC 13D/A 1 a031816a.htm AMENDMENT NO. 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* ARIAD Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 04033A100 (CUSIP Number) Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steamboat Road, 3rd |
|
| March 18, 2016 |
AMENDMENT TO AGREEMENT This AMENDMENT (the “Amendment”) is made as of March 17, 2016, by and among ARIAD Pharmaceuticals, Inc. |
|
| March 14, 2016 |
ARIAD Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Comm |
|
| March 14, 2016 |
ARIAD ANNOUNCES APPOINTMENT OF MANMEET S. SONI AS CHIEF FINANCIAL OFFICER EX-99.1 Exhibit 99.1 News Release ARIAD ANNOUNCES APPOINTMENT OF MANMEET S. SONI AS CHIEF FINANCIAL OFFICER Cambridge, MA, March 11, 2016?ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Manmeet S. Soni, 38, as executive vice president, chief financial officer and treasurer, effective March 21, 2016. He will report to Paris Panayiotopoulos, president and chief executiv |
|
| February 29, 2016 |
ARIAD Pharmaceuticals 10-K (Annual Report) 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 29, 2016 |
EX-21.1 Exhibit 21.1 SUBSIDIARIES OF ARIAD PHARMACEUTICALS, INC. Subsidiary Jurisdiction of Organization % Owned ARIAD Pharma S.A. Greece 100 % ARIAD Pharma Ltd. United Kingdom 100 % ARIAD Securities Corporation Massachusetts, United States 100 % ARIAD Pharmaceuticals (Cayman) Inc. Cayman Islands 100 % ARIAD Pharmaceuticals (Cayman) L.P. Cayman Islands 99.9999 %* ARIAD Pharmaceuticals (Japan) GK J |
|
| February 29, 2016 |
EX-4.1 Exhibit 4.1 . ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $.001 ARIAD COMMON STOCK THIS CERTIFICATE IS TRANSFERABLE IN CANTON, MA, JERSEY CITY, NJ AND COLLEGE STATION, TX Certificate Number ZQ00000000 THIS CERTIFIES THAT ARIAD PHARMACEUTICALS, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE MR. SAMPLE & MRS. SAMPLE & MR. SAMPLE & MRS. SAMPLE ** Mr. A |
|
| February 23, 2016 |
Exhibit 99.1 ARIAD Reports 2015 Financial Results, Provides 2016 Product Revenue Guidance and Outlines Company Progress Iclusig Net Product Revenue Guidance for 2016 in the Range of $190 Million to $200 Million Filing for U.S. Marketing Approval of Brigatinib Expected This Year Conference Call Scheduled Today at 8:30 a.m. ET CAMBRIDGE, Mass.-(BUSINESS WIRE)-February 23, 2016-ARIAD Pharmaceuticals, |
|
| February 23, 2016 |
Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Comm |
|
| February 10, 2016 |
ARIAD Pharmaceuticals 3G/A (Passive Acquisition of More Than 5% of Shares) ariadpharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3 )* Name of issuer: ARIAD Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 04033A100 Date of Event Which Requires Filing of this Statement: December 31, 2015 Check the ap |
|
| February 10, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Ariad Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04033A100 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| January 13, 2016 |
EX-3.3 Exhibit 3.3 CERTIFICATE OF ELIMINATION OF SERIES C CONVERTIBLE PREFERRED STOCK OF ARIAD PHARMACEUTICALS, INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware ARIAD PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware (the ?Company?), DOES HEREBY CERTIFY: First: Pursuant to Section 151 of the General Corporation L |
|
| January 13, 2016 |
EX-3.2 Exhibit 3.2 CERTIFICATE OF ELIMINATION OF SERIES B CONVERTIBLE PREFERRED STOCK OF ARIAD PHARMACEUTICALS, INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware ARIAD PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware (the ?Company?), DOES HEREBY CERTIFY: First: Pursuant to Section 151 of the General Corporation L |
|
| January 13, 2016 |
ARIAD Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Co |
|
| January 13, 2016 |
EX-99.1 Exhibit 99.1 Building Shareholder Value January 2016 J. P. Morgan Health care Conference A R I A D Pharmaceuticals , Inc . David Sachs Non-small cell lung cancer ARIAD clinical trial patient Some of the statements in this presentation constitute ?forward looking statements? under the Private Securities Litigation Reform Act of 1995. Such statements are subject to factors, risks and uncerta |
|
| January 13, 2016 |
ARIAD ANNOUNCES ELECTION OF ALEX DENNER AS CHAIRMAN OF THE BOARD OF DIRECTORS EX-99.2 Exhibit 99.2 News Release ARIAD ANNOUNCES ELECTION OF ALEX DENNER AS CHAIRMAN OF THE BOARD OF DIRECTORS Cambridge, MA ? January 10, 2016 ? ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the election of Alexander J. Denner, Ph.D., as chairman of its board of directors in a unanimous vote effective January 8, 2016. Dr. Denner joined the ARIAD Board of Directors in February 2014 a |
|
| January 13, 2016 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF ELIMINATION OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF ARIAD PHARMACEUTICALS, INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware ARIAD PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware (the ?Company?) DOES HEREBY CERTIFY: First: Pursuant to Section 151 of the General Corpo |
|
| January 13, 2016 |
ARIAD Pharmaceuticals 8-A12B/A 8-A12B/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 3) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 22-3106987 (State or other jurisdiction of incorporation) (IRS Employer Iden |
|
| January 13, 2016 |
ARIAD ANNOUNCES TERMINATION OF SHAREHOLDER RIGHTS PLAN EX-99.3 Exhibit 99.3 News Release ARIAD ANNOUNCES TERMINATION OF SHAREHOLDER RIGHTS PLAN Cambridge, MA, January 11, 2016?- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its Board of Directors has unanimously approved the termination of the Company?s Section 382 Rights Agreement, or the Rights Plan, originally adopted on October 31, 2013, effective immediately. The Rights Plan and |
|
| January 13, 2016 |
EX-3.4 Exhibit 3.4 RESTATED CERTIFICATE OF INCORPORATION OF ARIAD PHARMACEUTICALS, INC. (Pursuant to Sections 141 and 245 of the General Corporation Law of the State of Delaware) ARIAD Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?Delaware General Corporation Law?), DOES HEREBY CERTIFY |
|
| January 13, 2016 |
[Remainder of page intentionally left blank] EX-4.1 Exhibit 4.1 SECOND AMENDMENT dated as of January 8, 2016 (this ?Amendment?), to the SECTION 382 RIGHTS AGREEMENT dated as of October 31, 2013, as amended as of June 24, 2014 (as so amended and in effect from the date hereof, the ?Rights Agreement?), between ARIAD PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and COMPUTERSHARE TRUST COMPANY, N.A., as Rights Agent (the ?Right |
|
| December 18, 2015 |
ARIAD NAMES PARIS PANAYIOTOPOULOS AS ITS PRESIDENT AND CHIEF EXECUTIVE OFFICER Exhibit 99.1 News Release ARIAD NAMES PARIS PANAYIOTOPOULOS AS ITS PRESIDENT AND CHIEF EXECUTIVE OFFICER Cambridge, MA, December 18, 2015 ?- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its Board of Directors has voted unanimously to appoint Paris Panayiotopoulos President and Chief Executive Officer (CEO), effective January 1, 2016. Panayiotopoulos joins ARIAD from his current |
|
| December 18, 2015 |
Executive Employment Agreement Exhibit 10.1 Executive Employment Agreement ARIAD Pharmaceuticals, Inc. (the “ Company”), a Delaware corporation, and Paris Panayiotopoulos (the “ Employee”), an individual, enter into this Executive Employment Agreement as of December 16, 2015 (the “ Agreement”). WHEREAS, the Company wishes to offer the Employee employment according to the following terms and conditions; and WHEREAS, the Employee |
|
| December 18, 2015 |
Exhibit 10.2 FORM OF RESTRICTED STOCK UNIT AGREEMENT GOVERNED BY THE TERMS, CONDITIONS AND LIMITATIONS OF THE ARIAD PHARMACEUTICALS, INC. 2014 LONG-TERM INCENTIVE PLAN This Restricted Stock Unit Agreement (this ? Restricted Stock Unit Agreement?) certifies that the Board of Directors of ARIAD Pharmaceuticals, Inc. (the ? Company ?) has granted an unvested right to receive shares of Common Stock, $ |
|
| December 18, 2015 |
Exhibit 10.3 FORM OF STOCK OPTION AGREEMENT GOVERNED BY THE TERMS, CONDITIONS AND LIMITATIONS OF THE ARIAD PHARMACEUTICALS, INC. 2014 LONG-TERM INCENTIVE PLAN This Stock Option Agreement (this ? Option Agreement?) certifies that the Board of Directors of ARIAD Pharmaceuticals, Inc. (the ? Company ?) has granted an option (the ? Option ?) to purchase shares of the Company ?s common stock, $.001 par |
|
| December 18, 2015 |
ARIAD Pharmaceuticals (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2015 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Comm |
|
| November 3, 2015 |
EX-99.1 Exhibit 99.1 News Release ARIAD REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS AND PROGRESS ON STRATEGIC OBJECTIVES Conference Call Scheduled Today at 8:30 a.m. ET Cambridge, MA, November 3, 2015- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the third quarter of 2015, including revenue from sales of Iclusig® (ponatinib). The Company also provided an update |
|
| November 3, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K 1 d73398d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2015 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction |
|
| September 11, 2015 |
ARIAD Pharmaceuticals CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2015 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Comm |
|
| August 21, 2015 |
ARIAD Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2015 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Co |
|
| August 5, 2015 |
ARIAD Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2015 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) |
|
| August 5, 2015 |
EX-99.1 Exhibit 99.1 News Release ARIAD REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS AND PROGRESS ON STRATEGIC OBJECTIVES Conference Call Scheduled Today at 8:30 a.m. ET Cambridge, MA, August 5, 2015? ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter of 2015, including revenue from sales of Iclusig? (ponatinib). The Company also provided an update |
|
| July 29, 2015 |
EX-99.1 Exhibit 99.1 News Release ARIAD TO RECEIVE UP TO $200 MILLION THROUGH ICLUSIG NON-DILUTIVE SYNTHETIC-ROYALTY FINANCING WITH PDL BIOPHARMA Funding to support initiation of first-line study of brigatinib in ALK+ NSCLC and commercial launch readiness for brigatinib Cambridge, MA ? July 29, 2015 ? ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will receive $100 million in c |
|
| July 29, 2015 |
ARIAD Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2015 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) |
|
| July 27, 2015 |
ARIAD Pharmaceuticals CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21 , 2015 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commiss |
|
| July 24, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2015 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) |
|
| June 25, 2015 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 7, 2015 |
EX-99.1 Exhibit 99.1 News Release ARIAD REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS AND PROGRESS ON STRATEGIC OBJECTIVES Conference Call Scheduled Today at 8:30 a.m. ET Cambridge, MA, May 7, 2015? ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the first quarter of 2015, including revenue from sales of Iclusig? (ponatinib). The Company also provided an update on co |
|
| May 7, 2015 |
ARIAD Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2015 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commis |
|
| April 29, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* ARIAD Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 04033A100 (CUSIP Number) Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steamboat Road, 3rd Floor Greenwich, CT 06830 203-302-2330 |
|
| April 29, 2015 |
ARIAD Pharmaceuticals CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2015 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commiss |
|
| April 29, 2015 |
[Remainder of Page Intentionally Left Blank] Exhibit 10.1 AGREEMENT This AGREEMENT (the ? Agreement?) is made as of April 28, 2015 by and among ARIAD Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the ? Company?), and the persons and entities listed on Schedule A hereto (collectively, the ? Sarissa Group?). In consideration of the covenants and promises set forth herein, and for other goo |
|
| April 29, 2015 |
ARIAD Pharmaceuticals CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2015 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commiss |
|
| April 29, 2015 |
[Remainder of page intentionally left blank.] Exhibit 10.2 April 28, 2015 Harvey J. Berger, M.D. ARIAD Pharmaceuticals, Inc. 26 Landsdowne Street Cambridge, MA 02139-4234 Re: Retirement Agreement Dear Harvey: This retirement letter agreement (this ? Agreement?) is intended to amend the Amended and Restated Employment Agreement by and between you and ARIAD Pharmaceuticals, Inc. (the ? Company?), dated as of April 30, 2010 (the ? Employment Agr |
|
| April 29, 2015 |
ARIAD Enters into Settlement Agreement with Sarissa Capital Management Exhibit 99.1 ARIAD Enters into Settlement Agreement with Sarissa Capital Management CAMBRIDGE, Mass.-(BUSINESS WIRE)-Apr. 29, 2015 - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it has reached an agreement to settle its current proxy contest with Sarissa Capital Management. In addition, ARIAD’s founder, Harvey J. Berger, M.D., has informed the Board of Directors of his decision |
|
| April 29, 2015 |
ARIAD Enters into Settlement Agreement with Sarissa Capital Management Exhibit 99.1 ARIAD Enters into Settlement Agreement with Sarissa Capital Management CAMBRIDGE, Mass.-(BUSINESS WIRE)-Apr. 29, 2015 - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it has reached an agreement to settle its current proxy contest with Sarissa Capital Management. In addition, ARIAD?s founder, Harvey J. Berger, M.D., has informed the Board of Directors of his decision |
|
| April 29, 2015 |
ARIAD Founder, Harvey J. Berger, M.D., to Retire as Chairman and Chief Executive Officer Exhibit 99.2 ARIAD Founder, Harvey J. Berger, M.D., to Retire as Chairman and Chief Executive Officer CAMBRIDGE, Mass-(BUSINESS WIRE)-Apr. 29, 2015 - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its founder, Harvey J. Berger, M.D., has informed the Board of his decision to retire as chairman and chief executive officer (CEO) upon the appointment of his successor or December 31, |
|
| April 29, 2015 |
ARIAD Founder, Harvey J. Berger, M.D., to Retire as Chairman and Chief Executive Officer Exhibit 99.2 ARIAD Founder, Harvey J. Berger, M.D., to Retire as Chairman and Chief Executive Officer CAMBRIDGE, Mass-(BUSINESS WIRE)-Apr. 29, 2015 - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its founder, Harvey J. Berger, M.D., has informed the Board of his decision to retire as chairman and chief executive officer (CEO) upon the appointment of his successor or December 31, |
|
| April 29, 2015 |
[Remainder of Page Intentionally Left Blank] Exhibit 99.1 AGREEMENT This AGREEMENT (the “Agreement”) is made as of April 28, 2015 by and among ARIAD Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), and the persons and entities listed on Schedule A hereto (collectively, the “Sarissa Group”). In consideration of the covenants and promises set forth herein, and for other good a |
|
| April 29, 2015 |
[Remainder of page intentionally left blank.] Exhibit 10.2 April 28, 2015 Harvey J. Berger, M.D. ARIAD Pharmaceuticals, Inc. 26 Landsdowne Street Cambridge, MA 02139-4234 Re: Retirement Agreement Dear Harvey: This retirement letter agreement (this ? Agreement?) is intended to amend the Amended and Restated Employment Agreement by and between you and ARIAD Pharmaceuticals, Inc. (the ? Company?), dated as of April 30, 2010 (the ? Employment Agr |
|
| April 29, 2015 |
[Remainder of Page Intentionally Left Blank] Exhibit 10.1 AGREEMENT This AGREEMENT (the ? Agreement?) is made as of April 28, 2015 by and among ARIAD Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the ? Company?), and the persons and entities listed on Schedule A hereto (collectively, the ? Sarissa Group?). In consideration of the covenants and promises set forth herein, and for other goo |
|
| March 25, 2015 |
ARIAD ANNOUNCES DISMISSAL OF SHAREHOLDER CLASS ACTION LAWSUIT IN FEDERAL DISTRICT COURT EX-99.1 Exhibit 99.1 News Release ARIAD ANNOUNCES DISMISSAL OF SHAREHOLDER CLASS ACTION LAWSUIT IN FEDERAL DISTRICT COURT Cambridge, MA. ? March 25, 2015 ? ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the United States District Court for the District of Massachusetts dismissed the shareholder class action lawsuit filed in late 2013 against the Company and certain of its officers |
|
| March 25, 2015 |
ARIAD Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2015 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) |
|
| March 13, 2015 |
ARIAD Announces Dismissal of Shareholder Derivative Lawsuit in Federal District Court Exhibit 99.1 ARIAD Announces Dismissal of Shareholder Derivative Lawsuit in Federal District Court CAMBRIDGE, Mass.-(BUSINESS WIRE)-March 10, 2015-ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced today that the United States District Court for the District of Massachusetts dismissed the shareholder derivative lawsuit filed in late 2013 against the Company and certain of its officers and direct |
|
| March 13, 2015 |
ARIAD Pharmaceuticals ARIAD PHARMACEUTICALS, INC. 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2015 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commiss |
|
| February 26, 2015 |
ARIA / ARIAD Pharmaceuticals, Inc. DEFA14A - - SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| February 25, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* ARIAD Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 04033A100 (CUSIP Number) Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steamboat Road, 3rd Floor Greenwich, CT 06830 203-302-2330 |
|
| February 20, 2015 |
SC 13D/A 1 a021315.htm AMENDMENT NO. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* ARIAD Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 04033A100 (CUSIP Number) Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steamboat Road, 3rd |
|
| February 19, 2015 |
Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2015 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Comm |
|
| February 19, 2015 |
Exhibit 99.1 ARIAD Reports 2014 Financial Results, Provides 2015 Financial Guidance and Outlines Strategic Objectives Iclusig Net Product Revenue Guidance for 2015 in the Range of $130 Million to $140 Million Three New Iclusig Clinical Trials Planned to Begin This Year CAMBRIDGE, Mass.-(BUSINESS WIRE)-February 19, 2015-ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for |
|
| February 17, 2015 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* ARIAD Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04033A100 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule p |
|
| February 10, 2015 |
ARIA / ARIAD Pharmaceuticals, Inc. / VANGUARD GROUP INC Passive Investment ariadpharmainc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: ARIAD Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 04033A100 Date of Event Which Requires Filing of this Statement: December 31, 2014 Check the appropriate |
|
| January 14, 2015 |
Exhibit 99.2 Path to Value and Profitability Elsa So Non-small cell lung cancer ARIAD clinical trial patient Harvey J. Berger M.D. Chairman and Chief Executive Officer ARIAD Pharmaceuticals, Inc. 01.14.2015 J.P. Morgan Healthcare Conference Some of the statements in this presentation constitute “forward looking statements” under the Private Securities Litigation Reform Act of 1995. Such statements |
|
| January 14, 2015 |
Exhibit 99.1 ARIAD Announces Key Strategic Objectives for 2015 Expected to Lead Company to Profitability in Three Years Iclusig Commercial Opportunity Expected to Expand - Three New Clinical Trials to Begin in 2015, including a Global, Randomized Trial of Iclusig vs. Nilotinib in Second-Line CML CAMBRIDGE, Mass.-(BUSINESS WIRE)-January 13, 2015-ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today anno |
|
| January 14, 2015 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2015 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commi |
|
| January 7, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2015 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commis |
|
| January 7, 2015 |
Exhibit 99.1 ARIAD Announces Phase 2 Dose-Ranging Trial of Iclusig (Ponatinib) to Begin by Mid-2015 Randomized Global Trial to Evaluate Safety and Efficacy of Iclusig at Three Starting Doses CAMBRIDGE, Mass.-(BUSINESS WIRE)-January 6, 2015-ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it has concluded consultations with U.S. and European health authorities regarding the design of |
|
| December 30, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2014 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) ( |
|
| December 30, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2014 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) ( |
|
| December 30, 2014 |
EX-99.1 Exhibit 99.1 News Release ARIAD AND OTSUKA ANNOUNCE CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR ICLUSIG® TO TREAT LEUKEMIAS IN JAPAN AND NINE OTHER ASIAN COUNTRIES • ARIAD to receive upfront payment of USD 77.5 million and subsequent milestone-based payments • Otsuka to obtain rights in ten Asian countries to Iclusig, a newest-generation treatment for patients with refractory chroni |
|
| December 11, 2014 |
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial Exhibit 99.1 ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial SAN FRANCISCO & CAMBRIDGE, Mass.-(BUSINESS WIRE)-December 8, 2014-ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced long-term follow up from its pivotal Phase 2 trial of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intoleran |
|
| December 11, 2014 |
Exhibit 99.2 ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial ~ Median Follow-up in Trial Now Four Years CAMBRIDGE, Mass. & SAN FRANCISCO-(BUSINESS WIRE)-December 9, 2014-ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term follow up data from the Phase 1 trial of Iclusig® (ponatinib), its approved |
|
| December 11, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2014 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commi |
|
| December 11, 2014 |
Exhibit 99.3 ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leukemia CAMBRIDGE, Mass. & SAN FRANCISCO-(BUSINESS WIRE)-December 9, 2014-ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced safety and efficacy follow-up data on Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in patients with a baseline T315I mut |
|
| November 6, 2014 |
ARIA / ARIAD Pharmaceuticals, Inc. CORRESP - - CORRESP November 6, 2014 VIA EDGAR AND OVERNIGHT MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| November 5, 2014 |
Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2014 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commi |
|
| November 5, 2014 |
Exhibit 99.1 ARIAD Reports Third Quarter 2014 Financial Results and Development Progress Conference Call Scheduled Today at 8:30 a.m. ET CAMBRIDGE, Mass.-(BUSINESS WIRE)-November 5, 2014-ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the third quarter of 2014, including revenue from sales of Iclusig® (ponatinib). The Company also provided an update on corporate dev |
|
| October 28, 2014 |
ARIA / ARIAD Pharmaceuticals, Inc. CORRESP - - Correspondence October 28, 2014 VIA EDGAR AND OVERNIGHT MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| October 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2014 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commi |
|
| October 24, 2014 |
Exhibit 99.1 ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe CAMBRIDGE, Mass. & LAUSANNE, Switzerland-(BUSINESS WIRE)-October 24, 2014-ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted its final opinion on Iclus |
|
| October 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2014 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-36172 22-3106987 (State or other jurisdiction of incorporation) (Commissi |
|
| October 10, 2014 |
ARIAD and Bellicum Announce Revised License Agreement for ARIAD’s Cell-Signaling Technology Exhibit 99.1 ARIAD and Bellicum Announce Revised License Agreement for ARIAD’s Cell-Signaling Technology CAMBRIDGE, Mass. & HOUSTON-(BUSINESS WIRE)-October 6, 2014-ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) and Bellicum Pharmaceuticals, Inc. today announced a restructuring of their license agreement for ARIAD’s cell-signaling technology. ARIAD will receive $50 million in exchange for a fully paid u |
|
| September 29, 2014 |
ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer Exhibit 99.1 ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer MADRID & CAMBRIDGE, Mass.-(BUSINESS WIRE)-September 29, 2014-ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Pha |
|
| September 29, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2014 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Com |
|
| September 18, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2014 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporat |
|
| September 5, 2014 |
ARIA / ARIAD Pharmaceuticals, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 5, 2014 REGISTRATION NO. |
|
| September 5, 2014 |
ARIA / ARIAD Pharmaceuticals, Inc. S-8 - - FORM S-8 Form S-8 As filed with the Securities and Exchange Commission on September 5, 2014 REGISTRATION NO. |
|
| September 2, 2014 |
SC 13D/A 1 a082814.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* ARIAD Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 04033A100 (CUSIP Number) Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steamboat Road, 3rd |
|
| August 27, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2014 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction (Commission (I.R.S. Emplo |
|
| August 27, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2014 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction (Commission (I.R.S. Emplo |
|
| August 27, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2014 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commis |
|
| August 20, 2014 |
SC 13D/A 1 s13da2.htm SCHEDULE 13D/A, AMENDMENT #2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* ARIAD Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 04033A100 (CUSIP Number) Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steamboa |
|
| August 8, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2014 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commiss |
|
| August 6, 2014 |
Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2014 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36172 22-3106987 (State or other jurisdiction of incorporation) (Commiss |
